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Abstract
Melanoma is the most aggressive type of skin cancer and has very high rates of mortality. An early stage
melanoma can be surgically removed, with a survival rate of 99%. However, metastasized melanoma is difficult
to cure. The 5-year survival rates for patients with metastasized melanoma are still below 20%. Metastasized
melanoma is currently treated by chemotherapy, targeted therapy, immunotherapy and radiotherapy. The
outcome of most of the current therapies is far from optimistic. Although melanoma patients with a mutation
in the oncogene v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) have an initially higher positive
response rate to targeted therapy, the majority develop acquired drug resistance after 6 months of the therapy.
To increase treatment efficacy, early diagnosis, more potent pharmacological agents, and more effective
delivery systems are urgently needed. Nanotechnology has been extensively studied for melanoma treatment
and diagnosis, to decrease drug resistance, increase therapeutic efficacy, and reduce side effects. In this review,
we summarize the recent progress on the development of various nanoparticles for melanoma treatment and
diagnosis. Several common nanoparticles, including liposome, polymersomes, dendrimers, carbon-based
nanoparticles, and human albumin, have been used to deliver chemotherapeutic agents, and small interfering
ribonucleic acids (siRNAs) against signaling molecules have also been tested for the treatment of melanoma.
Indeed, several nanoparticle-delivered drugs have been approved by the US Food and Drug Administration
and are currently in clinical trials. The application of nanoparticles could produce side effects, which will need
to be reduced so that nanoparticle-delivered drugs can be safely applied in the clinical setting.
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Abstract: Melanoma is the most aggressive type of skin cancer and has very high rates of 
mortality. An early stage melanoma can be surgically removed, with a survival rate of 99%. 
However, metastasized melanoma is difficult to cure. The 5-year survival rates for patients 
with metastasized melanoma are still below 20%. Metastasized melanoma is currently 
treated by chemotherapy, targeted therapy, immunotherapy and radiotherapy. The outcome 
of most of the current therapies is far from optimistic. Although melanoma patients with a 
mutation in the oncogene v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) have 
an initially higher positive response rate to targeted therapy, the majority develop acquired 
drug resistance after 6 months of the therapy. To increase treatment efficacy, early diagnosis, 
more potent pharmacological agents, and more effective delivery systems are urgently 
needed. Nanotechnology has been extensively studied for melanoma treatment and diagnosis, 
to decrease drug resistance, increase therapeutic efficacy, and reduce side effects. In this 
review, we summarize the recent progress on the development of various nanoparticles for 
melanoma treatment and diagnosis. Several common nanoparticles, including liposome, 
polymersomes, dendrimers, carbon-based nanoparticles, and human albumin, have been used 
to deliver chemotherapeutic agents, and small interfering ribonucleic acids (siRNAs) against 
signaling molecules have also been tested for the treatment of melanoma. Indeed, several 
nanoparticle-delivered drugs have been approved by the US Food and Drug Administration 
and are currently in clinical trials. The application of nanoparticles could produce side effects, 
which will need to be reduced so that nanoparticle-delivered drugs can be safely applied in 
the clinical setting.
Keywords: metastasis, early detection, nanoparticle-delivered, PI3K/Akt
Introduction
Melanoma, originated from melanocytes, is the most aggressive type of skin cancer.1,2 
Although melanoma represents only a very small proportion of skin cancer incidence, 
it accounts for the vast majority of skin cancer deaths.3 For example, there were more 
than 2 million new cases of skin cancer in USA in 2012, and among them only 75,000 
(3.75%) cases were melanoma.4 However, melanoma accounts for 9000 (75%) deaths 
among the total 12,000 deaths caused by skin cancer in 2012. An early-stage melanoma 
that has not spread or metastasized to other organs can be removed by surgery, with high 
survival rates. It has been reported that the cure rate for those patients with removable 
melanoma reached 97%−99.8% after chemosurgery.5 However, metastasized irremovable 
melanoma needs to be treated by other standard therapies, such as chemotherapy, 
radiotherapy, targeted therapy, and immunotherapy.6,7 Unfortunately, treatment outcomes 
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are not satisfactory and patients’ responses to most of these 
therapies are very poor.8
At present, the most common drug used for the treatment 
of melanoma is dacarbazine (DTIC), which is a US Food and 
Drug Administration (FDA)-approved, first-line treatment 
for patients with wild-type melanomas.9 Although in vitro 
experiments showed that DTIC produced cytotoxicity in 
many melanoma cell lines, the response to DTIC was only 
5%−10% when used alone.10 The use of targeted therapy 
against mutated oncogene v-Raf murine sarcoma viral 
oncogene homolog B1 (BRAF) showed a dramatically 
increased response, reaching 80%.11,12 Unfortunately, 
most patients will have acquired drug resistance to BRAF 
inhibitors after 6 months of treatment, resulting in loss of 
clinical efficacy. The median survival time of patients with 
metastasized melanoma is only 6−10 months, and the 5-year 
survival rate is less than 20%.13−15 Therefore, improved 
treatment efficiency is urgently needed for melanoma. To 
achieve this, improvement in the diagnosis and treatment is 
required. Early detection of melanoma can lead to surgical 
removal before metastasis. Identification of the involved 
gene mutations and understanding of the dysregulation in the 
key signaling pathways can help in the design of proper 
therapeutic regimes. Successful treatment will also rely on 
the discovery of specific, more potent pharmacological agents 
and efficient delivery systems.
Nanotechnology involves the design, development, 
characterization, and application of materials in nanoscale 
and has been extensively studied for medical applications.16 
Applications of nanotechnology in the diagnosis and 
treatment of melanoma have been studied extensively 
and have advanced the study of melanoma in several 
aspects.17,18 Nanoparticles provide an effective drug delivery 
system, allowing anticancer drugs to reach the cancer site 
specifically and thus greatly improving treatment efficacy. 
Nanotechnology also has helped in diagnosis, by allowing 
imaging agents to be packed into nanoparticles that reach 
the cancer. In this review, we summarize the recent progress 
in the application of nanotechnology in the diagnosis and 
treatment of melanoma.
Common nanoparticles used 
in melanoma treatment
Rapid progress in understanding the biology of cancer cells 
has been made in the past decade. However, the treatment 
outcomes of cancers have not changed much. The failure 
of anticancer therapies is considered to be due to the side 
effects of most anticancer drugs, low concentrations of 
the drugs at the tumor site, and the development of drug 
resistance.19,20 Nanoparticles have been studied extensively 
for drug delivery, to increase anticancer treatment efficacy. 
Compared with conventional drug delivery approaches, 
nanoparticle-mediated delivery of anticancer drugs brings 
several remarkable advantages. First, drugs delivered by 
nanoparticles may have a longer biological life, due to 
packaging protection, and may be concentrated in the 
site of cancer due to enhanced permeability and retention 
(EPR) at cancer sites.21 EPR is caused by the leakiness of 
tumor vasculature as well as poor lymphatic drainage.22 
Therefore, nanotechnology increases treatment efficacy 
and decreases side effects. For example, Doxil® (Janssen 
Biotech, Horsham, PA, USA), which is doxorubicin (Dox) 
formulated in liposomes containing polyethylene glycol 
(PEG), has a 100-fold longer circulation half-life and 
sevenfold lower cardiocytotoxicity than has free Dox.22 
Second, a nanoparticle can contain multiple drugs and 
thus will facilitate combination therapy. It is known that 
the combination of chemotherapy with immunotherapy or 
targeted therapy produces much more effective treatment 
outcomes.16 Third, nanoparticles can protect drugs made 
of fragile small interfering ribonucleic acid (siRNA) or 
proteins, from biochemical degradation in the human body. 
This is due to the stealth-like features of nanoparticles.23 
Fourth, nanoparticles produce a constant release of delivered 
drugs. Furthermore, nanoparticles can be designed to have 
multiple functions, such as targeting to cancer cells and 
producing image contrast.24 Many nanoparticles have been 
studied for the treatment of melanoma, including liposomes, 
dendrimers, polymersomes, carbon-based nanoparticles, 
inorganic nanoparticles, and protein-based nanoparticles 
(Table 1).16,25,26
A liposome is a sphere consisting of a lipid bilayer that 
contains aqueous core for hydrophilic drugs.24 Hydrophobic 
drugs can be contained between the two layers. Liposome was 
invented more than 50 years ago and was the first nanoparticle 
used in medicine.27 Liposome is prepared by sonicating a 
lipid, with a process involving emulsification. Homogeneous 
nanosized liposomes can be achieved by filtering through a 
0.2 µM membrane.28 Furthermore specific ligands against 
tumor antigens can be attached to the liposome surface so 
that the nanoparticles can target cancer cells specifically.29,30 
Liposomes have been used to carry chemotherapeutic drugs, 
immunocytokines, and siRNA, to increase treatment efficacy 
for melanoma.16 Similar structural nanoparticles have been 
designed, such as the cubosome and niosome, which consist 
of lipids.24
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Dendrimers are synthetic polymers with branches that 
form a tree-like structure, which encapsulate drugs within 
their internal cavities.31 Recently, tecto(dendrimers) have been 
made, which introduce covalent linkages between dendrimer 
building blocks to achieve higher architectural structures.32 
Schilrreff et al made a dendrimer by using amine-terminated 
polyamidoamine (PAMAM) generation 5 (G5) as a core and 
carboxyl-terminated PAMAM G2.5 as the shell and demon-
strated it was toxic to the melanoma cell line SK-Mel-28, 
but not to normal keratinocytes.32 The immunogenicity of 
dendrimers may cause unwanted systemic immune reaction, 
which may limit their therapeutic application.
Polymersomes are composed of amphiphilic block 
copolymers, such as polylactic acid and poly(ε-caprolactone), 
formulated to become nanoparticles.33 Polymersomes can 
encapsulate either hydrophilic or hydrophobic drugs.34 They 
are more stable and less permeable to small water-soluble 
molecules than are liposomes.35 Their surface can also be 
attached with ligands for targeting cells and controllable 
release. Polymersomes have been used to deliver Dox for 
treating melanoma and demonstrated to be preferentially 
taken up by melanoma cells.36 The nanoparticles markedly 
reduced tumor growth in a melanoma xenograft model.
Carbon-based nanoparticles were first made in 1985 
and known as fullerenes, which were composed of 
60 carbon atoms.37 In 1991, a carbon nanotube was 
established. Recently, nanodiamonds were used to deliver 
drugs against melanoma.16 Carbon-based nanoparticles have 
been shown to increase the efficacy of chemotherapy in 
melanoma cells.16,38 Chaudhuri et al38 showed that a single-
walled carbon nanotube loaded with Dox induced melanoma 
cell death in a dose-dependent fashion in vitro and abrogated 
tumor growth in a xenograft melanoma model.
Inorganic nanoparticles made from materials such as 
silica and aluminum have also been applied in melanoma 
therapy. Silica can be made multiporous (which is then 
called mesoporous silica) to carry more drugs than as a 
simple sphere.39 A layered double hydroxide nanoparticle 
is made by layering a hydroxyl (-OH) group on inorganic 
materials, to carry drugs.40 This has been shown to increase 
immune response to a deoxyribonucleic acid (DNA) vaccine 
in a melanoma mouse model.41 At present, the capability of 
layered double hydroxide to carry enough small molecular 
drug is still a major problem.
Human albumin has also been used to make nanoparticles 
for the treatment of melanoma.42 An albumin-based 
nanoparticle, Abraxane® (Abraxis Bioscience, Summit, NJ, 
USA) (also known as ABI-007 or nanoparticle albumin 
bound [nab]-paclitaxel [PTX]) has been approved by the 
FDA for clinical use. PTX is non−water soluble, and nonionic 
surfactant, such as Cremophor® EL (BASF Corp), is used to 
make a suspension.43 This increases side effects, including 
Table 1 Characteristics and side effects of common nanoparticles used in the study of melanoma treatment
Nanoparticle Sample drugs delivered 
for melanoma
Clinical use Characteristics Side effects Possible solutions
Liposomes Cisplatin 
vincristine  
Doxorubicin
Doxil High biocompatibility 
High biodegradability 
High cell uptake rates 
Low drug encapsulation 
efficacy 
High cost
Hand-foot syndrome (skin  
rash, swelling, redness, pain) 
Toxicity to normal cells 
due to positive charge
Increase drug loading 
to reduce liposomes 
to be used 
Use of natural lipids
Dendrimers Doxorubicin 
Cisplatin 
Paclitaxel 
vincristine
Not yet 
available
High stability 
High solubility 
High drug encapsulation 
Uniform size 
Low biodegradation
Surface charge 
 
Accumulation in kidney 
and reticuloendothelium
Attach anionic polymer 
 
Control the size
Polymersomes Doxorubicin  
Paclitaxel 
Cyclodextrin
Not yet 
available
High biodegradability 
Controlled release 
Not uniform size
Accumulation in kidney 
and reticuloendothelium
Control the size
Carbon-based 
nanoparticles
Doxorubicin Not yet 
available
High biocompatibility 
High photostability 
Small size 
Not biodegradable
Inflammation 
 
ROS production
Adjust the size
Human albumin Paclitaxel Nab-paclitaxel 
(Abraxane®)
High solubility 
High stability 
Low toxicity
Side effects related with 
delivered drugs
Reduce dosage for a 
specific drug through 
combination therapies
Abbreviations: nab-paclitaxel, nanoparticle albumin bound−paclitaxel; ROS, reactive oxygen species.
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acute hypersensitivity reactions, anemia, and cardiovascular 
events.43 Albumin has been used to conjugate PTX with 
Cremophor, to reduce these side effects. Clinical trials have 
shown that Abraxane was better tolerated and more effective 
against melanoma than was free PTX.44,45 However, a recent 
report showed that poly(gamma-L-glutamylglutamine)-PTX 
was more effective in reducing the growth of xenografted 
B16 melanoma cells than was Abraxane and had less side 
effects.46
The applications of nanotechnology 
in the conventional therapies 
of melanoma
Nanotechnology has been applied to most conventional 
therapies for melanoma. It has been demonstrated that the 
nanodelivery of drugs for chemotherapy, targeted therapy, 
immunotherapy, and photodynamic therapy has greatly 
increased treatment efficacy.16,25,26
Chemotherapy
Chemotherapy is the most common conventional therapy 
for melanoma. Chemotherapeutic agents kill both malignant 
and normal cells that are in division.47 Therefore, they 
are very toxic, and this limits the dosage to be used. The 
common chemotherapeutic agents used in melanoma are 
DTIC, vinblastine, and temozolomide. The response rates, 
however, are very low. It has been reported that the response 
to DTIC, vinblastine, and temozolomide was 7%, 9.5%, 
and 28%, respectively in a clinical trial with 64 patients.7 
Nanoparticles have been used to deliver chemotherapeutic 
agents and demonstrated to increase treatment efficacy and 
reduce side effects. Zhang et al showed that delivering the 
chemotherapeutic agent Dox by gold nanoparticles was very 
effective against a melanoma cell line.48 Lo Prete et al applied 
a cholesterol-rich nanoemulsion (termed “LDE”) to deliver 
etoposide in a mouse model of melanoma.49 It decreased side 
effects, increasing maximum tolerated dose fivefold, and 
increased the inhibition of tumor growth by concentrating 
etoposide at the tumor site (a fourfold higher concentration 
in tumor than with free etoposide). Ndinguri et al packed Dox 
in a nanoparticle with additional antibody against CD44, to 
specifically target malignant cells.50 The nanoparticle reduced 
the tumor size by 60% compared with untreated tumor.
Nab-PTX (Abraxane) has been approved by the FDA for 
the treatment of breast cancer. Hersh et al reported a Phase II 
clinical trial using nab-PTX (Abraxane) in both previously 
treated and untreated melanoma patients.45 The response 
rates were 2.7% and 21.6%, respectively. In the study, 
22% chemotherapy-naive patients discontinued treatment 
due to grade 3 or 4 neuropathy, alopecia, neutropenia, and 
fatigue. Kottschade et al51 conducted a Phase II clinical trial 
using nab-PTX and carboplatin in advanced melanoma, in 
41 chemotherapy-naive and 35 previously-treated melanoma 
patients. The response rate was 25.6% in the chemotherapy-
naive cohort and was 8.8% in the previously-treated cohort. 
The severe side effects were neutropenia, thrombocytopenia, 
neurosensory problems, fatigue, nausea, and vomiting. In 
another clinical trial, Kottschade et al52 showed vascular 
endothelial growth factor (VEGF) antibody increased the 
effect of nab-PTX. Ott et al showed that the combination of 
a B cell lymphoma protein (Bcl)-2 antisense oligonucleotide, 
temozolomide, and nab-PTX produced a response of 40.6%.53 
Similar side effects to that revealed in Kottschade et al’s study 
were also reported.
Targeted therapy
Intracellular signaling pathways play a key role in the 
carcinogenesis and prognosis of many cancers, including 
melanoma, and many inhibitors have been developed for the 
treatment of cancer (Table 2).54,55 These pathways are activated 
either by genetic defects or environmental factors.56 Obesity 
is a common disease that is characterized by dysregulated 
energy balance and metabolic disturbance.57 It can increase 
cancer incidence and results in poorer prognosis through the 
activation of multiple signal pathways, including mitogen-
activated protein kinase (MAPK), phosphoinositide 3-kinase 
(PI3K), and signal transducer and activator of transcription 
3 (STAT3).54,58−60 The MAPK pathway is a major pathway 
in melanoma. It has been studied extensively in melanoma, and 
Table 2 Common inhibitors of the pMAPK and PI3K/Akt 
pathways
Signaling 
molecule
Inhibitors References
RTK Imatinib, dasatinib, sorafenib Inamdar55
Ras Tipifarnib, R115777, BMS-214662, 
L-778123
Inamdar55
Raf Sorafenib, PLX4032, XL281, RAF-265 Inamdar55
Mek AZD6244, U0126, PD0325901, CI-1040, 
XL518, AZD8330, ARRY-162, ARRY-300, 
perifosine, erucyl-phosphocholine
Chen54 
Inamdar55
ERK DHMEQ Inamdar55
Akt Ly294002, Bez235, PI103 Inamdar54,55
mTOR Rapamycin, Bez235, PI103 Inamdar54,55
NF-kB Curcumin, plumbagin Inamdar55
Abbreviations: Akt, protein kinase B; ERK, extracellular signal-regulated kinase; MEK, 
mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; NF-kB, 
nuclear factor-kappaB; PI3K, phosphoinositide 3-kinase; pMAPK, phosphorylated 
mitogen-activated protein kinase; Raf, rapidly accelerated fibrosarcoma; Ras, rat 
sarcoma protein (subfamily of small GTPases); RTK, receptor tyrosine kinase.
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many inhibitors have been developed to inhibit this pathway 
for treatment. Activation of the MAPK pathway in melanoma 
has been shown to be caused by the activation of mutations 
in its components; the mutation rate is 50%−70% for BRAF, 
15%−30% for NRAS, 2% for KRAS and 1% for HRAS.61−63 
The PI3K/protein kinase B (Akt) pathway can synergistically 
affect the MAPK pathway to promote the development of 
melanoma.64 The signaling pathways of MAPK and PI3K/
Akt and their crosstalk are shown in Figure 1. Both pathways 
regulate a broad range of target proteins.58,65 A common 
survival pathway downstream of both MAPK and PI3K/Akt 
is the mitochondrial apoptosis signal pathway that includes 
the Bcl-2 family of proteins, including both proapoptotic 
and antiapoptotic signals. Furthermore, inhibition of both 
the MAPK and PI3K/Akt pathways has been shown to have 
a synergistic effect in the treatment of melanoma.66
Nanotechnology has been used to deliver certain inhibitors 
of the MAPK pathway.55,67 A chitosan nanoparticle was used 
to deliver the downstream target protein VEGF siRNA and 
was demonstrated to improve the therapeutic effect.68 Yin et al 
used functional graphene oxide to deliver a plasmid-based 
STAT3 siRNA and showed significantly reduced xenografted 
tumor growth.69 Indeed, STAT3 is considered as a key mediator 
in melanoma which promotes brain metastasis.70 Inhibition of 
phosphorylated STAT3 has been shown to increase efficacy 
of tumor necrosis factor (TNF)-alpha for melanoma.71 
A nanoparticle has also been designed to carry siRNA against 
the oncogene c-Myc to target melanoma cells B16F10 and 
demonstrated effectiveness against melanoma.72 Tran et al 
prepared a nanoparticle to contain both siRNAs against BRAF 
and Akt3 which markedly increased the anticancer effect.73
Targeting the mitochondrial pathway
As discussed above, a major downstream mediator of PI3K/
Akt and MAPK is the mitochondrial apoptotic pathway. 
The pathway is regulated by proapoptotic proteins and 
antiapoptotic proteins. The former includes Bak, Bax, Bid, 
Bim, Bcl-associated death promoter (BAD), Noxa, and 
PUMA. The latter includes Bcl-2, Bcl-xL, Bcl-w, Mcl-1, 
and A1.74 Both PI3 K and MAPK can increase antiapoptotic 
Ras
BRAF
MEK
ERK1/2
mTORC1
Mitochondria
Bcl-2
Bcl-XL
VEGF
Akt
PDK
PIP3PIP2
PI3K
NF-
kB MNK1/2
MSK1/2
RSK
PPAR
ELK1
ETS
STAT3
Figure 1 Signaling pathways in melanoma.
Notes: Oncoprotein Ras activates both the MAPK and PI3K/Akt survival pathways. Ras can stimulate BRAF activity, which in turn, activates MEK and ERK1/2. Ras also 
activates PI3K, which catalyzes PIP2 into PIP3. PIP3 increases Akt activity via PDK. Both Akt and ERK1/2 act on the mitochondrial apoptosis signaling pathway and mTORC1. 
Akt also targets vEGF and NF-kB. ERK1/2 can also activate STAT3 and other transcriptional factors, such as MNK1/2, MSK1/2, ELK, ETS, RSK, PPAR, ELK1, and ETS. 
Abbreviations: Akt, protein kinase B; Bcl-2, B cell lymphoma protein 2; Bcl-XL, B cell lymphoma protein extra large; BRAF, v-Raf murine sarcoma viral oncogene homolog 
B1; ELK1, member of the E-twenty-six transcriptional family; ERK, extracellular signal-regulated kinase; ETS, E-twenty-six (transcriptional family); MAPK, mitogen-activated 
protein kinase; MEK, MAPK kinase; MNK1, 2, MAPK-interacting kinases 1, 2; MSK1, 2, stress-activated kinases 1, 2; mTORC1, mammalian target of rapamycin complex 1; 
NF-kB, nuclear factor-kappaB; PI3K, phosphoinositide 3-kinase; PIP2, phosphatidylinositol-4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate; PDK, putative 
3-phosphoinositide-dependent kinase; PPAR, peroxisome-proliferator-activated receptor; Ras, rat sarcoma protein (subfamily of small GTPases); RSK, 90-kDa ribosomal S6 
protein kinase; STAT3, signal transducer and activator of transcription 3; vEGF, vascular endothelial growth factor.
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protein expression and decrease proapoptotic protein 
expression and thus increase the ratio of antiapoptotic 
proteins/proapoptotic proteins. This plays a key role in 
melanoma initiation, maintenance, and drug resistance.75 
Reversal of this ratio, either by inhibition of antiapoptotic 
proteins or overexpressing proapoptotic proteins, has been 
used for the treatment of melanoma. For example, inhibition 
of Bcl-2 by ABT-737 caused melanoma cell apoptosis.76
Nanotechnology has been found to increase the therapeutic 
effect of Bcl-2 inhibition. In nude mice, oblimersen 
(an antisense oligonucleotide against Bcl-2) decreased 
xenografted melanoma growth.77 The dual application of 
oblimersen with DTIC in patients in a Phase III clinical trial 
resulted in increased effectiveness compared with DTIC 
alone (9 vs 7.8 months, respectively, for overall survival; 2.6 
vs 1.6 months, respectively, for progression-free survival; 
13.5% vs 7.5%, respectively, for overall response; 2.8% 
vs 0.8%, respectively, for complete response; and 7.3% vs 
3.6%, respectively for durable response).78 A nanoparticle 
was made to carry Bcl-2 siRNA (as well as Myc and VEGF) 
for the treatment of melanoma.79 It was shown that this 
resulted in Bcl-2 reduction in both messenger ribonucleic 
acid (mRNA) and protein levels. This increased anticancer 
effects both in vitro and in vivo. Oblimersen has been used 
in Phase I clinical trial in combination with temozolomide 
and nab-PTX and proved more effective in patients with 
advanced melanoma.53
Immunotherapy
Immunotherapy is used to improve the immune response of 
patients with melanoma, to increase the clearance of cancer 
cells, especially those already damaged by chemotherapy or 
targeted therapy. Without immunotherapy to clear damaged 
cancer cells, the efficacy of treatment would not be achieved, 
as these damaged cells may self-repair and become more 
malignant. In melanoma, several immunocytokines have been 
shown to have initial effects, but these effects are limited 
by side effects.80 The commonly used immunostimulators 
in melanoma are interleukin (IL)-2, interferon (IFN)-alpha, 
ipilimumab, and thymosin alpha 1.81−84 IL-2 has been reported 
to increase remission time but that high-dose IL-2 may cause 
acute side effects and possibly death.80,83
Nanoparticles have been used to deliver immunotherapy 
drugs, to reduce side effects.85,86 Yao et al prepared a novel 
nanoparticle containing IL-2 and tested it in a mouse 
model with xenografted melanoma.87 The nanoparticle was 
made from low−molecular weight polyethylenimine (600 
Da), which was linked to β-cyclodextrin, conjugated with 
folate, and further mixed with IL-2 plasmid. It was shown 
that the particle inhibited tumor growth and prolonged the 
survival of the melanoma-bearing mice.87 He et al used a 
biodegradable polymer, poly(polycaprolactone), to make a 
nanoporous miniature device for local delivery of cytokine 
IFN-alpha and showed constant slow release of IFN-alpha.88 
Speiser et al prepared a nanoparticle containing cytosine-
phosphodiester-guanine (CpG)-loaded virus-like particle 
carrying melanoma antigen recognized by T cells 1 (Mart-1) 
to target melanoma cells, and this nanoparticle produced 
a strong immune response against melanoma, including 
increased cytotoxic CD8 T-cell responses.89 Furthermore, two 
ligands have been loaded into a nanoparticle. For example a 
nanoparticle with both CD40 and Toll-like receptor (TLR) 
stimulators was used to increase dendritic cells (DCs) and 
CD8-T-cells.90 A nanoparticle combining TLR 7 and 9 
ligands has also been demonstrated to exert a synergistic 
effect.91 A nanoparticle made from lipopolyplexes was used 
to deliver melanoma antigen mRNA. A mannosylated form 
of nanoparticle has been shown to increase the efficacy of 
transfection into DCs.86 In an animal model, mannosylated 
and histidylated lipopolyplexes showed a greater ability to 
reduce tumor growth than did the sugar-free form. A possible 
explanation is that these nanoparticles can be better taken up 
by DCs and thus induced more tumor-specific cytotoxic T 
lymphocytes. Therefore, it is clear that nanotechnology can 
be used to improve immunotherapy in melanoma.
Photodynamic therapy (PDT)
PDT is a therapy that applies nontoxic, light-sensitive 
compounds, which become toxic after light exposure.92 
In PDT, a photosensitizer is administered and then excited by 
suitable irradiation, emitted from a light source, to generate 
single oxygen (¹O
2
), superoxide anion radical (O
2
−), and 
hydroxyl radical (OH) for therapy.92 It has been demonstrated 
in a mouse model with xenografted melanoma that PDT 
induced significant apoptosis, necrosis, and tumor growth 
arrest and thus prolonged the survival time of the animals 
bearing melanoma.92
Camerin et al used nanoparticles to carry Zn[II]-
phthalocyanine disulfide (C11Pc) to test PDT treatment 
efficacy in a mouse model of xenograft melanoma.93 It was 
found that gold nanoparticle−associated C11Pc had more 
effective treatment outcomes. The nanoparticle had greater 
accumulation than did free C11Pc, and the ratio of C11Pc 
between melanoma and skin increased from 2.3 to 5.5. 
Electron microscopy showed that the C11Pc delivered by 
nanoparticles caused more damage in blood capillaries and 
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endothelial cells than did the free C11Pc.93 In other work, 
a nanoparticle was used to deliver two photosensitizers, to 
increase therapeutic efficacy in melanoma.94
Magnetite nanoparticles
Sato et al designed a magnetite nanoparticle by conjugating 
N-propionyl-cysteaminylphenol with magnetite and used this 
in a B16F1 xenograft mouse model.95 Electron microscopy 
demonstrated this particle appeared only in melanoma 
cells. It was shown that the melanoma cells were degraded 
after the application of an external alternating magnetic 
field to increase the temperature in the tumor to 43°C. The 
nanoparticle had a 1.7 to 5.4-fold greater effect than did the 
magnetite used alone. A recent study showed that curcumin 
further increased the efficacy of magnetite nanoparticles.96
Inhibition of the drug detoxification 
system
The accumulation of anticancer drugs in cancer cells is 
closely associated with anticancer effects. Drug resistance 
is often caused by activation of the cellular detoxification 
system, which includes the drug pump, permeability 
glycoprotein (P-gp), and the drug metabolism enzyme, 
cytochrome P450 (CYP).97,98 Both P-gp and CYP are 
regulated by several nuclear receptors, such as pregnane X 
receptor (PXR), farnesoid X receptor (FXR), and constitutive 
androstane receptor (CAR). Nanoparticle-delivered Dox or 
PTX has been shown to inhibit P-gp expression and has a 
much greater effect against melanoma that does free Dox 
and PTX.99 Further, siRNA against the mRNAs for these 
proteins has been carried by nanoparticles for the treatment 
of cancers. It has been shown in breast cancer that the 
inhibition of P-gp by nanoparticle-delivered Bcl-2, Myc, 
and PXR siRNAs produced a greater anticancer effect than 
did the inhibition of Bcl-2, Myc, and PXR by free siRNA.100 
However, this has not been studied in melanoma and may 
warrant investigation.
The application of nanotechnology 
for the diagnosis of melanoma
The aim of initial diagnosis is to make a judgment about 
whether melanoma is present and at what developmental 
stage is the melanoma. An early diagnosis is critical to 
obtain high survival rates for melanoma patients. Beyond 
naked-eye examination and histological observation, many 
new technologies have been used to aid diagnosis, such as 
dermoscopy, total body photography, reflectance confocal 
microscopy, multispectral digital imaging analysis, and 
RNA microarray.101,102 In metastasized melanoma, molecular 
signatures of the melanoma may be identified so that a 
proper treatment regime can be made. This is important, as 
the molecular alterations are associated with intracellular 
signaling pathway changes, clinical features, and responses 
to different treatment regimes. Molecular diagnosis could 
be included in the routine diagnosis for melanoma in the 
near future.103 More and more newly developed techniques 
are used in the molecular diagnosis of melanoma, such as 
tissue array, proteomics, and DNA sequencing.104 During the 
treatment of melanoma, judgment of efficacy is needed to 
assess whether the approach used is appropriate and whether 
there is any better way to increase the patient’s response to 
treatment. This determination includes imaging tumor size 
and vascular structure. Nanotechnology has been proven to 
be a valuable tool to improve the diagnosis of melanoma.
Nanoparticle quantum dots (QDs) have been used for 
the early detection of melanoma, due to their photophysical 
properties, including exceptional brightness, size-tunable 
emission wavelength, broad excitation spectrum with narrow 
emission profile, and excellent photostability.105,106 QDs can 
be conjugated with cancer-specific molecules, such as folic 
acid or antibodies recognizing antigens overexpressed in 
cancer cells.107 Zheng et al used PEG-COOH capped highly 
fluorescent CdSe/ZnS core/shell QDs conjugated with 
antibody against CD146 to detect CD146 overexpressed 
melanoma cells in cultured and fixed cells.108 Flow cytometry 
and confocal microscopy showed the positive cells to have 
high brightness, photostability, and specificity. Kim et al 
developed a coculture system containing both melanoma 
cells and normal melanocytes to test QDs conjugated with 
antibodies (ab732 or Ab733) against melanoma.106 It was 
shown that melanoma cells could be distinguished from 
melanocytes.
Melanoma is a heterogeneous disease.109 Each type may 
have different mechanisms with different gene mutations 
and the activation of different signaling pathways and 
thus, different responses to anticancer drugs. Therefore, 
it is necessary, for efficient treatment, to identify the 
molecular signatures for each melanoma patient, and to plan 
personalized treatment.110 For example, melanoma can be 
classified into one of two categories depending on whether 
a BRAF mutation exists, as the BRAF inhibitor vemurafenib 
is only effective for those with a BRAF mutation. Patients 
with the BRAF mutation have as high as an 80% response to 
vemurafenib.111,112 Therefore, detection of a BRAF mutation 
is of importance for the selection of treatment regimes. 
Nanotechnology has been used to improve the detection of 
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BRAF mutation.113 In an assay using microcantilever arrays, 
a BRAF-specific oligonucleotide probe was used to detect 
mutated BRAF. The probe was able to detect mutated BRAF 
at the concentration of 500 pM but normal BRAF at a 50-fold 
higher concentration. As the total RNA needed for the assay 
is only 20 ng/µL, no polymerase chain reaction (PCR) was 
needed for the assay.
Dendrimers have been used for monitoring metastasized 
melanoma. A recent study attempted to make a dendrimer 
decorated with arginine-glycine-aspartic acid and fluores-
cence.114 It was expected that the nanoparticle would accumu-
late in the tumor and then be viewed through fluorescence or 
nuclear magnetic resonance (NMR) spectroscopy so that the 
tumor size and vascular structure could be detected. However, 
it was found that the particles accumulated in the kidney 
and reticuloendothelial system. Further study is needed to 
achieve the goal of using dendrimers for the diagnosis of 
metastasized melanoma.
Theranostic nanomedicine in 
melanoma
Recently, theranostic nanomedicine has been developed, which 
uses nanoparticles for both diagnosis and treatment.115,116 
By employing the capacity of nanoparticles to deliver 
multiple agents in a single nanoparticle, imaging agents are 
incorporated into the nanoparticles so that the action of the 
therapeutic agents can be monitored in a real-time fashion. 
This could help to assess drug distribution and release or to 
evaluate drug response and efficacy. The information can also 
be useful for researchers, to guide the formulation of new 
nanoparticles with desired distribution characteristics. At 
present the most commonly used nanoparticles for theranostic 
purpose are liposomes and polymersomes. Imaging agents for 
magnetic resonance imaging (MRI), radionuclide imaging, 
and fluorescence imaging have been studied.
Theranostic nanomedicine has already been applied 
in melanoma study.117 Vannucci et al constructed a 
nanoparticle based on the heavy chain of the human protein 
ferritin to test in melanoma.42 The nanoparticle was loaded 
with α-melanocyte stimulating hormone to specifically 
target melanoma, coated with PEG molecules to prevent 
binding to its physiological receptors, and loaded with the 
fluorescent reagent rhodamine for the purpose of imaging. 
The nanoparticle was demonstrated by confocal microscopy 
to bind specifically to melanoma cells rather than to colon 
cancer cells. For nanotheranostics, Ma et al used a lipid-based 
nanomicelle to deliver docetaxel.118 A fluorescent dye DiR 
(1,1′-dioctadecyl-3,3,3′,3′-tetramethyl indotricarbocyanine 
iodide) was coated on the hydrophobic core of micelles to 
detect the distribution of the nanoparticle. The formulation 
of these imaging agents as nanoparticles has facilitated 
the examination of their distribution in tumor cells and 
pharmacokinetic profiling. Further studies are warrant to 
enable their use for clinical application.
The application of nanotechnology 
in the establishment of metastasis 
models
Metastasis is the main reason for death due to cancer. 
Therefore, it is necessary to understand the biology of 
melanoma metastasis in order to provide better approaches 
for its treatment. It has been recognized that metastasis is 
not a passive process.119−121 Cancer cells need to undergo 
many alterations to pass barriers, such as anoikis, to reach 
destination and colonization. The process of metastasis 
is complicated by the control of intracellular signaling 
pathways.122 Understanding the process will facilitate 
treatment to stop the metastasis. In melanoma, the most 
common metastatic sites are brain, liver, lung, bone, and the 
gastrointestinal tract.123 Brain metastasis is one of the major 
reasons for melanoma-caused deaths because the blood−brain 
barrier reduces treatment efficacy. An animal model has 
been established to mimic the metastasis of melanoma to 
the brain, and nanotechnology has been used to improve 
the model.123
At present, the model is made by injecting melanoma 
cells directly into the left cardiac ventricle to bring the cells 
to brain.124 The model has been used to study the role of 
growth factor−induced signaling pathways in metastasis, and 
treatment efficacy.70,71,124 However, these models are not well 
established, and reproducibility is poor. Nanotechnology has 
been used to track the injected cells.125 Melanoma cells were 
labeled with superparamagnetic iron oxide nanoparticles 
and visualized by MRI. This technique contributes to the 
establishment of a reproducible and predictable metastasis 
model and could be useful for the prediction of therapeutic 
outcomes.
Future directions
Acquired drug resistance to BRAF-inhibitors is a major 
issue in the treatment of melanoma. For example, the initial 
response to vemurafenib is 80%, but the majority of patients 
will develop drug resistance. The mechanisms for such 
resistance could be diverse, including the overexpression of 
P-gp, increased drug metabolism, enhanced self-repairing 
ability, altered drug targets, and the activation of intracellular 
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signaling pathways.126 The use of nanotechnology in dealing 
with this issue could be helpful but is still challenging. So far, 
not many studies have been done to employ nanotechnology 
to overcome drug resistance. Khdair et al created a single 
multidrug nanoparticle with both chemotherapeutic and 
PDT agents that would target melanoma cells, in order 
to overcome acquired drug resistance.127 Tran et al used a 
nanoparticle with both sorafenib and ceramide to prevent 
acquired drug resistance.128 However, the mechanisms for 
acquired drug resistance in melanoma have been shown to 
be diverse. The use of different drugs in nanoparticles will 
be needed depending on the mechanisms of acquired drug 
resistance.
Evaluation and the avoidance of severe side effects caused 
by nanoparticles could be critical for the successful clinical 
application of nanoparticles for drug delivery. Cytotoxicity 
to normal cells in relation to nanoparticles could be caused 
by size-related toxicity and the leaching of components.129 
Large-size nanoparticles can accumulate in the endoplasmic 
reticulum system. Further, the immunogenicity of nano-
particles can cause autoimmunity. Many different types of 
nanoparticles have been tested; each may have different side 
effects, and some side effects caused by nanoparticles may 
be fatal.129 However, overall, the side effects of nanoparticles 
are not very well understood at present, and many more 
studies are needed.
Conclusion
Metastatic melanoma is still a difficult disease to treat. 
The key for improving the treatment efficacy is to have a 
better understanding of the pathogenesis of the disease, 
early diagnosis and identification of individual molecular 
typing, as well as novel and effective drug delivery systems. 
Nanotechnology has offered the potential to improve the 
diagnosis and treatment of melanoma. It has been dem-
onstrated that nanoparticle-delivered anticancer drugs 
concentrate in tumor tissue and thus increase treatment 
efficacy and reduce side effects. Nanoparticles have also 
been shown to carry imaging agents to detect melanoma 
and BRAF mutation. Further studies are needed to avoid 
the side effects caused by some nanoparticles so that they 
can be applied clinically.
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